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Abstract
Cognitive changes in older women receiving chemotherapy are poorly understood. We examined
self-reported cognitive function for older women who received adjuvant chemotherapy on Cancer
and Leukemia Group B (CALGB) 49907. CALGB 49907 randomized 633 women aged ≥65 with
stage I–III breast cancer to standard adjuvant chemotherapy (cyclophosphamide–methotrexate–5-
fluoro-uracil or doxorubicin–cyclophosphamide) versus capecitabine. We examined self-reported
cognitive function in 297 women (CALGB 361002) who enrolled on the quality of life substudy
and had no gross impairment on cognitive screening. Women were evaluated using an 18-item
instrument at six time points (baseline through 24 months). At each time point for each patient, we
calculated a cognitive function score (CFS) defined as the mean response of items 1–18 and
defined impairment as a score >1.5 standard deviations above the overall average baseline score.
Differences in scores by patient characteristics were evaluated using a Kruskal–Wallis test. A
linear mixed-effects model was used to assess CFSs by treatment over time. Among 297 women,
the median age was 71.5 (range 65–85) and 73 % had performance status of 0. Baseline
depression and fatigue were reported in 6 and 14 % of patients, respectively. The average CFS at
baseline was 2.08 (corresponding to “normal ability”), and baseline cognitive function did not
differ by treatment regimen (p = 0.350). Over 24 months, women reported minimal changes at
each time point and insignificant differences by treatment arm were observed. In a healthy group
of older women, chemotherapy was not associated with longitudinal changes in self-reported
cognitive function.
Keywords
Cognitive function; Older women; Breast cancer; Age
Introduction
The majority of breast cancer diagnoses occur in older women [1], many of whom will be
recommended to receive chemotherapy to lower their risk of disease recurrence. Although
many toxicities of chemotherapy have been well elucidated for younger women, the side
effects that older women experience are less defined, largely as a result of the
underrepresentation of older women in most clinical trials. There has been some suggestion
that older patients experience greater chemotherapy-related toxicity compared with younger
women, despite similar risk reductions in relapse-free and overall survival with treatment [2,
3]. However, the extent of cognitive decline in older women who receive chemotherapy
remains poorly studied.
The potential for “chemo-brain” and “chemo-fog,” terms often used to describe the
cognitive changes women report while receiving chemotherapy, is of great concern to the
patient and survivorship community and is a widely discussed entity in the media and cancer
literature [4, 5]. Prior studies have reported variable cognitive changes in 15–50 % of cancer
patients who undergo chemotherapy [6–13], with observed difficulties in attention, learning,
and processing speed during treatment [11] that typically improve over time [9, 14]. The risk
factors for developing cognitive changes during cancer-directed therapies are unknown but
may include specific treatments (high-dose chemotherapy, bone marrow transplant) [15, 16],
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genetic predisposition [17], menopausal symptoms [13], inflammatory markers [18],
depression [16], fatigue [19], and other potential factors, particularly age [20–22]. However,
studying changes in cognitive function is challenging, particularly because the changes
observed on objective testing of cognition often do not correlate with subjective report and
may not fully reflect patients’ experiences [10, 23–26]. Self-reported changes in cognitive
function during and after chemotherapy are associated with psychological distress, quality of
life, health status, and fatigue [6, 19, 27].
Small studies in populations of older patients receiving chemotherapy have shown
conflicting results on whether cognitive dysfunction is a significant clinical problem, and
longitudinal assessments have not been consistently included [21, 28–32]. In the quality of
life substudy Cancer and Leukemia Group B (CALGB) 361002, we examined changes in a
self-reported cognitive function scale in older women with breast cancer who received
adjuvant chemotherapy on CALGB protocol 49907. CALGB 49907 randomized women to
receive standard chemotherapy (either cyclophosphamide–methotrexate–5-fluorouracil
[CMF] or doxorubicin–cyclophosphamide [AC] by provider choice) or capecitabine [33].
This study, one of the few prospective trials dedicated to older patients, demonstrated
superiority in relapse-free survival and overall survival for patients treated with standard
chemotherapy compared with capecitabine. Multiple preplanned, prospective, ancillary
studies were embedded within 49907, including examination of quality of life (QOL) [34].
For the QOL substudy, the first 368 women who spoke English or Spanish were asked to
participate. The longitudinal data collection for the QOL substudy provided a unique
opportunity to conduct a secondary analysis of cognitive function for older women who
received chemotherapy. We assessed longitudinal, subjective changes in cognitive function
for 297 women on the QOL substudy (CALGB 361002).
Patients and methods
Population and data collection
CALGB 49907 enrolled 633 patients aged ≥65 during 2001–2006 at 149 nationwide centers
with the objective of evaluating the potential noninferiority of an oral, potentially less toxic
adjuvant chemotherapeutic agent (capecitabine) to standard chemotherapy (CMF or AC, by
provider choice). Patients were eligible for the parent study if they had at least a 1-cm,
operable, invasive breast cancer with negative surgical margins and no distant metastases,
Eastern Cooperative Oncology Group performance status of 0–2, adequate organ function,
expected survival of more than 5 years, and no medical condition that would make protocol
treatments unreasonably hazardous. Women were excluded because of a concurrent
malignancy or a previous cancer with a risk of relapse >30 %. The full details of eligibility
for CALGB 49907 have been previously published [33]. Treatment arms were assigned
randomly in a 1:1 fashion to standard chemotherapy (CMF or AC) or capecitabine.
The QOL companion study simultaneously enrolled 350 of the first 368 patients on CALGB
49907 between 2002 and 2006 randomized to either standard chemotherapy (n = 182) or
capecitabine (n = 168) [34]. Women signed an institutional review board–approved
informed consent prior to participation. Patients were English- or Spanish-speaking and
passed an initial screening to rule out gross cognitive impairment using the Blessed
Orientation-Memory-Concentration (BOMC) test [35]. Those scoring 11 or higher on the
BOMC (n = 17) were considered to have significant impairment, making them ineligible.
Survey data regarding social support, stressful life events, toxicity, changes in physical
function, adherence to therapy, and neurobehavioral symptoms were collected on the QOL
study at six time points: (1) baseline, (2) mid-treatment, (3) within 1 month post-treatment,
(4) 12 months, (5) 18 months, and (6) 24 months. Results of the QOL substudy have been
previously published [34].
Freedman et al. Page 3













Among the 350 patients who participated in the QOL study, 334 patients completed at least
one assessment of cognitive function; 10 missed the baseline evaluation and 27 missed all
five follow-up assessments. These 37 patients were excluded from analyses with a final
sample size of 297 women (Fig. 1). The reasons for missing questionnaires over time often
corresponded to the timing of stopping protocol therapy and included the following: disease
progression (n = 1), toxicity (n = 8), death on study (n = 2), patient withdrawal after starting
or prior to starting treatment (n = 6), per protocol (n = 7), and other/missing reason (n = 3).
There were no withdrawals for cognitive toxicity specifically.
Measures
The Neurobehavioral Functioning and Activities of Daily Living (NBFADL) scale is a 60-
item scale that has been previously used and validated to assess cognitive issues in daily life
that affect functioning [36, 37]. The Memory, Cognitive and Concentration subscales of the
NBFADL were selected for the QOL study as a subjective cognitive function measure and
were administered as a telephone survey at all six time points along with the other
components of the QOL study. Patients who consented to participate were given a packet of
QOL questionnaires to complete before the telephone interview, at which time the
centralized research interviewer collected their answers [34]. The subscales included 18
questions that evaluated five domains of cognitive function including attention, problem-
solving, speed, new learning and prospective memory, and remote memory (Table 1).
Patients selected a response for each question ranging from 1 to 7 (1 = “above average” to 7
= “severe problems”).
Variables of interest
The primary variable of interest was cognitive function score (CFS), defined as the mean
response of items 1–18 from the Memory, Cognitive and Concentration subscale of the
NBFADL scale. Cognitive impairment was defined as a CFS at any time point that was >1.5
standard deviations (SDs) above the overall average baseline score [14].
Patient characteristics evaluated for association with CFS included treatment arm
assignment, treatment regimen, age, number of comorbid conditions according to the Older
American and Services (OARS) Questionnaire [38, 39], hormonal therapy, education level,
and stage of disease. Because of potential impact on cognitive function, we also examined
the occurrence of depression, anxiety, and fatigue at baseline according to the European
Organization for the Research and Treatment of Cancer (EORTC) Quality of Life (QLQ-
C30) questionnaire [40, 41] and the Hospital Anxiety and Depression Scale (HADS) [42].
The QLQ-C30 is a 30-question measure on global health status, function, and symptoms,
and it also includes two items on attention and memory. The HADS is a 14-question
measure on the frequency of depression- and anxiety-related symptoms (i.e., “I get sudden
feelings of panic” and “I look forward with enjoyment to things”). We defined the presence
of depression at baseline if participants answered “quite a bit” or “very much” to either of
the mood questions on the EORTC QLQ-C30 (“Over the last week, did you feel irritable?…
did you feel depressed?”) or had a HADS score ≥11 on the depression subscales. Baseline
anxiety was defined as a HADS score ≥11 on anxiety subscales [42]. Fatigue was defined by
having answered “quite a bit” or “very much” to a single question on the EORTC measure
(“Were you tired?”) [41].
Statistical analysis
Frequency distributions and means were used to describe baseline patient characteristics.
Associations among groups for categorical variables were assessed with chi-square and
Fisher’s exact tests. The differences in CFSs and baseline characteristics among groups were
compared with a Kruskal–Wallis test. For univariate analyses, we used a 0.05 type 1 error
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rate. A linear mixed-effects model with nominal time to each assessment as the repeated
variable was used to assess the differences in CFSs among treatment arms, assuming a
compound symmetric covariance structure and assuming that any missing data were missing
at random. All available data were used in the analyses of cognitive function over time.
Covariates included in the model were age, assessment, treatment arm, and an interaction
term between treatment arm and assessment. The type 1 error rate was adjusted to 0.01 to
reduce the chance of spurious significant findings. In addition, baseline characteristics for
women with<20 % missing data versus those with ≥20 % missing data (i.e., women with 1–
4 follow-up assessments missing after baseline) were compared. There were no differences
in baseline characteristics for women by the degree of missing data, with the exception of
rates of hormone receptor (HR)-positive status (72 % had HR-positive disease in those with
<20 % missing data versus 60 % with HR-positive disease in those with ≥20 % missing data,
p = 0.041). An exploratory analysis was performed on the women with baseline scores >1.5
SDs from the group baseline mean (n = 19) to determine how they differed from the
remaining cohort. Frequency distributions were used to describe cognitive impairment over
time.
Lastly, because our 18-item measure has not been validated previously outside of the
comprehensive NBFADL scale, we used Pearson correlations to examine whether the
EORTC questions for attention and memory impairment (“Have you had difficulty in
concentrating on things, like reading a newspaper or watching television?” and “Have you
had difficulty remembering things?”) correlated with our results from the NBFADL-based
CFS. For the correlation analysis, we averaged the scores between the two EORTC
questions and then converted to a 100-point scale as described in the EORTC scoring
manual [41]. All statistical analyses were performed by Alliance statisticians using SAS
v9.2 (Cary, NC, USA).
Results
There were 367 (350 eligible) women enrolled to the QOL portion of CALGB 49907 from
June 2002 through April 2006. Characteristics of the 297 women in this study are displayed
in Table 2. The median age of participants was 71.5 years (range 65–85). Over 70 % of
women had a performance status of zero, and 30 % reported four to ten comorbidities [38,
39]. Approximately 51 % of women reported having a high school education or less.
Baseline anxiety, depression, and fatigue were uncommon. Approximately 21 % of women
received AC, 32 % received CMF, and 47 % received capecitabine. Baseline characteristics
did not differ for women by treatment regimen received, with the exception of fatigue (i.e.,
21 % for CMF, 8 % for AC, and 13 % for capecitabine, p = 0.049). Of note, with the
exception of differences in age, patients included in this study were similar to women who
enrolled on the treatment component for CALGB 49907 (mean age 71.9 years for women on
this study versus 73.0 years on treatment component, p = 0.004).
At baseline, the average CFS was 2.08 (range 1.00–5.56), corresponding to nearly “normal
ability.” Women with worse cognitive function at baseline were less educated (p = 0.003)
and had more positive nodes (p = 0.022), more comorbid conditions (p = 0.002), more
fatigue (p = 0.020), and more anxiety (p = 0.010), although numerical differences between
subgroups were small (average CFSs range = 1.77–2.37 across all categories, corresponding
to “normal ability”) (Table 2). There were no differences in baseline CFSs by treatment
regimen (p = 0.350).
During the study period, the overall average CFSs by treatment arm remained within
“normal ability” (Table 3). At mid-treatment, within 1 month post-treatment, and at 12, 18,
and 24 months, adjusted CFSs ranged from 2.1 to 2.3. Results from the linear mixed-effects
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model also showed little variation in self-reported CFSs over time (Table 3). There were no
differences by treatment arm (Fig. 2) over time).
Cognitive impairment was observed in 19 (6 %) women at baseline, 19 (6 %) at mid-
treatment, 29 (10 %) at the end of the treatment, 31 (12 %) at 12 months post-treatment, 18
(7 %) at 18 months post-treatment, and 22 (9 %) at 24 months post-treatment. At 24 months,
14 of the 19 women had measures completed at both baseline and 24 months. Of these
women, nine reported impairment (64 %) at both time points. Although relative impairment
was observed in these patients by our definition, the numerical differences between time
points for nearly all patients were small.
Finally, the Pearson correlation coefficients for mean self-reported CFSs and the memory
and attention components of the EORTC were calculated at each time point and ranged in
magnitude from 0.539 to 0.680 (data not shown). These observations indicate that in
general, women who reported good memory and attention on the EORTC also reported good
cognitive function on the Neurobehavioral Scales form (and vice versa).
Discussion
We examined self-reported cognitive function for a prospective, large cohort of older
women with breast cancer who received adjuvant chemotherapy on a clinical trial. In this
healthy, older population with primarily normal self-reported cognitive function at baseline,
we observed minimal changes in cognitive function over time and minimal differences in
subjective cognitive function by treatment received. At 24 months, nearly all patients
reported normal cognitive function.
Prior studies on cognitive function changes in older women receiving systemic therapy have
shown variable results and have generally included small samples of women without
multiple longitudinal assessments or consistent inclusion of subjective report. Hurria et al.
[21] examined objective cognitive function in 31 patients aged 65 and older who received
adjuvant chemotherapy for breast cancer and demonstrated objective declines in cognitive
function in 25 % of patients (defined as a difference in 1 SD in 2 or more domains on
neuropsychological testing) from before chemotherapy to 6 months after completion of
chemotherapy, and 50 % reported subjective decline in cognitive function, which was most
pronounced in patients who reported pre-existing memory problems. Another study assessed
cognitive function longitudinally in older women undergoing chemotherapy and found
significant changes in processing speed and verbal ability compared with controls.
Impairment was worse among older women, although the mean age was 55 years and only
60 women received chemotherapy [20].
A meta-analysis assessing 30 cognitive function studies including over 800 women
receiving adjuvant chemotherapy for breast cancer showed only modest changes in verbal
and visuospatial ability for women on treatment. In this analysis, no differences by age were
observed, although the median age for women included in the analysis was 52.3 years [15].
Yamada et al. performed a focused examination for longer-term effects in 30 older women
who received chemotherapy 10 years prior to enrollment. Here, women who received
chemotherapy performed worse on objective cognitive function testing compared with
matched controls [29], demonstrating the importance of following women over time.
Overall, because of the small sample sizes and variable methodological approaches of these
studies, the evidence for cognitive function changes remains controversial and definitive
data are lacking.
Our study is the largest, prospective study to date of cognitive function in older women
receiving chemotherapy and included six time points, allowing for examination of the entire
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treatment and post-treatment trajectory. We also had individual information on comorbidity,
baseline cognitive function, tumor characteristics, and presence of fatigue, depression, and
anxiety, which are all factors that may impact cognitive function. Nevertheless, our study
has some limitations. First, we studied a highly selected population of older women in a
randomized trial who were healthy enough to receive chemotherapy and who passed an
initial cognitive function screening test, excluding women with gross cognitive dysfunction.
In addition, women had good performance status and organ function. Although our findings
cannot be generalized to all older patients, our observations are very relevant to healthy,
older women who are typically selected to receive chemotherapy. Second, our analyses did
not allow a comparison of cognitive function with a control group of older breast cancer
patients not receiving chemotherapy, a control group of older noncancer patients, or a
control group of younger women to assess impact of having cancer and/or cancer therapy as
well as age. Others have noted that a cancer diagnosis itself may have adverse effects on
cognition apart from any anxiety, fatigue, or depression [11, 19, 43, 44]. We also could not
evaluate age–treatment interactions since all patients were 65 and older. Ahles et al. [20]
have noted such interactions, and these will be important to confirm in future research.
Third, assignment to treatment with AC versus CMF within the standard treatment arm was
not random but was selected by providers, which may influence findings, although cognitive
function changes were rare for all study participants regardless of treatment received.
Fourth, our assessments of cognitive function have not been previously validated as a
measure independent from the complete NBFADL and are self-reported only. However,
arguably, how women feel about their cognitive changes may be more important from a
quality of life standpoint than any objective changes observed, and others have documented
the poor correlation between objective and subjective cognitive functional decline [10, 23–
26]. Lastly, because few women met the criteria for cognitive impairment and because
differences in scores over time were small, our ability to perform analyses assessing factors
associated with such impairment was limited.
In summary, older women on CALGB 49907 tolerated standard and nonstandard
chemotherapy without subjective declines in cognitive function over the first 24 months
after starting treatment. Although our study included a selected population of older women,
these findings are reassuring because of the concerns for cognitive decline in older women
receiving cancer-directed systemic therapy. Future studies should include consistent,
prospective, detailed subjective and objective assessments of cognitive and physical function
to further expand our knowledge about how our treatments impact older women with breast
cancer. Systematic studies on the various effects of chemotherapy on older patients will be
necessary to optimally serve and support this growing population of patients.
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Neurobehavioral assessments completed over the study period. *Seventeen patients were
deemed ineligible because they did not pass the Blessed Orientation-Memory-Concentration
test at screening
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Mean cognitive function score (CFS) by treatment arm over time. Mid-treatment,
doxorubicin–cyclophosphamide (AC): day 29; end of treatment, AC: 4–5 months. Mid-
treatment, cyclophosphamide–methotrexate–5-fluorouracil (CMF): day 77; end of treatment,
CMF: 6–7 months. Mid-treatment, capecitabine: day 63; end of treatment, capecitabine: 4–5
months. Error bars represent 95 % CI for the adjusted average cognitive function score
(CFS)
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Table 1
Questions and instructions from the 18-question measure
Neurobehavioral Scales form (domain assessed)
1 Ability to avoid losing train of thought; distractibility (attention)
2 Ability to focus on goals; carry out a plan (problem-solving)
3 Remembering events from long ago (remote memory)
4 Remembering new information told to you (new learning and prospective memory)
5 Attention and concentration (attention)
6 Ability to reason through a complicated problem (problem-solving)
7 Self-awareness of problems (problem-solving)
8 Remembering what you intended to do (new learning and prospective memory)
9 Ability to shift easily from one activity to the next (problem-solving)
10 Remembering appointments or meetings (new learning and prospective memory)
11 General alertness (attention)
12 Ability to think clearly (attention)
13 Remembering new information you have read (new learning and prospective memory)
14 Remembering where you put things (new learning and prospective memory)
15 Ease in initiating or starting activities by oneself (speed)
16 Ability to make decisions (problem-solving)
17 Remembering information learned long ago (new learning and prospective memory)
18 Ability to be flexible, rather than rigid or have overly set manner (problem-solving)
Patients were asked to “mark an X in a single box indicating the appropriate response for each task [marked 1–7]”
Response options for each item ranged from 1 to 7 and included the following: 1 = above average, 2 = normal ability, 3 = mild problem, 4 = mild to
moderate problem, 5 = moderate problem, 6 = moderate to severe problem, 7 = severe problem
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Table 2
Baseline cognitive function score by patient characteristics (n = 297)
Variable N (%) Baseline cognitive function scorea (standard deviation) p valueb
Age 0.598
 65–69 year 120 (40) 2.05 (0.43)
 70–79 year 166 (56) 2.10 (0.59)
 ≥80 year 11 (4) 1.95 (0.28)
Race 0.118
 White 259 (87) 2.05 (0.47)
 Black 32 (11) 2.27 (0.81)
 Other 3 (0) 2.07 (0.47)
 Unknown 3 (0) 2.37 (0.36)
Education 0.003
 Grades 1–11 35 (12) 2.33 (0.74)
 High school graduate 115 (39) 2.09 (0.42)
 Some college/junior college 82 (27) 2.06 (0.51)
 College/post-college/advanced 59 (20) 1.96 (0.51)
 Degree unknown 6 (2) 1.77 (0.60)
Tumor size 0.787
 ≤2 cm 129 (43) 2.07 (0.44)
 2–5 cm 156 (53) 2.10 (0.59)
 >5 cm 11 (4) 1.96 (0.38)
Number of positive lymph nodes 0.022
 0 88 (30) 2.03 (0.55)
 1–3 164 (55) 2.05 (0.44)
 4+ 44 (15) 2.27 (0.69)
Stage 0.228
 I 21 (7) 1.88 (0.45)
 IIA 117 (39) 2.11 (0.53)
 IIB 92 (31) 2.11 (0.58)
 IIIA 20 (7) 1.96 (0.32)
 IIIB 1 ( <1) 2.67 (n/a)
 Unknown 46 (15) 2.05 (0.44)
Hormone receptor statusc 0.150
 Negative 95 (32) 2.06 (0.65)
 Positive 202 (68) 2.08 (0.45)
HER2 status 0.379
 Negative 234 (79) 2.07 (0.45)
 Positive 44 (15) 2.18 (0.80)
 Unknown 19 (6) 1.97 (0.51)
ECOG performance status 0.265
 0 (Normal) 218 (73) 2.03 (0.42)
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Variable N (%) Baseline cognitive function scorea (standard deviation) p valueb
 1 (Ambulatory) 74 (25) 2.22 (0.72)
 2 ( <50 % time in bed) 5 (2) 2.21 (0.53)
Treatment arm 0.619
 Standard (AC or CMF) 157 (53) 2.10 (0.46)
 Capecitabine 140 (47) 2.06 (0.58)
Treatment received 0.350
 AC 95 (32) 2.08 (0.51)
 CMF 62 (21) 2.11 (0.37)
 Capecitabine 140 (47) 2.06 (0.58)
Tamoxifen use 0.527
 No 238 (80) 2.08 (0.54)
 Yes 58 (21) 2.08 (0.44)
 Unknown 1 (0.4) 1.22 (not applicable)
OARS number of comorbidities 0.002
 0 24(8) 1.93 (0.40)
 1 36 (21) 1.94 (0.42)
 2–3 120 (40) 2.06 (0.47)
 4–10 90 (30) 2.24 (0.63)
Fatigue 0.020
 No 252 (85) 2.05 (0.50)
 Yes 40 (13) 2.30 (0.64)
 Unknown 5 (2) 1.99 (0.09)
Depression 0.276
 No 280 (94) 2.07 (0.52)
 Yes 17 (6) 2.20 (0.43)
Anxiety 0.010
 No (score <11) 271 (91) 2.05 (0.48)
 Yes (score ≥11) 26 (9) 2.40 (0.74)
ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, ECOG Eastern Cooperative Oncology Group,
AC doxorubicin plus cyclophosphamide, CMF cyclophosphamide–methotrexate–5-fluorouracil, OARS Older American Resources and Services,
HADS Hospital Anxiety and Depression Scale, EORTC European Organization for the Research and Treatment of Cancer
a
Possible scores ranged from 1 to 7 (1 = above average and 7 = severe problem)
b
For differences in mean cognitive function score at baseline, by Kruskal–Wallis tests
c
Hormone receptor (HR) status defined as the following: negative = ER-negative and PR-negative; positive = ER-positive and PR-positive, ER-
negative/missing and PR-positive, or ER-positive and PR-negative/missing
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